Home › T-Cell Lymphoma › Wisconsin › Madison
T-Cell Lymphoma clinical trials in Madison, WI
3 studies for T-Cell Lymphoma are looking for participants at sites in and around Madison (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
RecruitingPhase 2
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
RecruitingPhase 3
- University of Wisconsin Carbone Cancer Center, Madison
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
RecruitingPhase 3
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
T-Cell Lymphoma trials in other cities
- New York City, NY13 studies
- Philadelphia, PA10 studies
- Baldwin Park, CA9 studies
- Boston, MA9 studies
- Houston, TX8 studies
- Atlanta, GA8 studies
- Chicago, IL6 studies
- Seattle, WA6 studies
- Columbus, OH6 studies
- Rochester, MN6 studies
- New Haven, CT5 studies
- Miami, FL5 studies
Other studies in Madison
- Prostate Cancer29 studies
- Colorectal Cancer22 studies
- Breast Cancer22 studies
- Metastatic Cancer21 studies
- Non-Small Cell Lung Cancer16 studies
- Acute Myeloid Leukemia16 studies
- Melanoma15 studies
- Cancer (all types)14 studies
- Ovarian Cancer13 studies
- Stomach Cancer11 studies
- Lung Cancer10 studies
- Pancreatic Cancer10 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.